The European Leadership Summit on Chronic Care, Amsterdam, The Netherlands

3-4 December, 2007, Amsterdam, The Netherlands
Organised under the high patronage of the European Commission, the event will convene senior executives from key organisations advancing chronic care in Europe including providers, payers, suppliers, customers, policy-makers and health officials.

The European Leadership Summit on Chronic Care is the forum where government and industry leaders share successful initiatives and best practices. So far, the agenda includes case studies from 12 different countries.

Through the support of our partner organizations, we are creating a truly international event, reaching key health leaders in over 40 countries. An international delegation will enjoy this two-day networking opportunity, featuring visionary keynote addresses, controversial debates, implementation case studies, tutorials and informal roundtable discussions.

Four focused summits will give attendees a unique opportunity to discuss pertinent issues in depth and determine actionable plans with their colleagues:

  • IT Infrastructures, Electronic Health Records and Chronic Care
  • Aligning Financial Incentives and Restructuring Care
  • Telehealth and Remote Monitoring
  • Empowering Patients and Supporting Self-Care

Two best practice seminars will also explore disease specific initiatives for:

  • Diabetes
  • Cardiovascular and Lung Diseases

For further information and registration, please visit: http://www.worldcongress.com/events/HL07080/

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...